8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): April 13, 2007

                           ARIAD Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)


       Delaware                      0-21696                     22-3106987
   (State or other                 (Commission               (I.R.S. Employer
    jurisdiction                   File Number)             Identification No.)
  of incorporation)


          26 Landsdowne Street, Cambridge, Massachusetts            02139
             (Address of principal executive offices)           (Zip Code)


       Registrant's telephone number, including area code: (617) 494-0400


                                 Not Applicable
          (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

|_|  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))




ITEM 8.01 Other Events.

          In a press release dated April 13, 2007, ARIAD Pharmaceuticals, Inc.
          announced that it has filed a claim against Amgen Inc. and certain
          affiliated entities (Amgen) and Wyeth alleging infringement of the
          pioneering U.S. patent covering methods of treating human disease by
          regulating NF-(kappa)B cell-signaling activity. The claim is in
          response to a lawsuit filed by Amgen against ARIAD in the United
          States District Court for the District of Delaware in April 2006
          seeking declaratory judgment that the claims of U.S. Patent No.
          6,410,516 (the `516 Patent) are invalid and that Amgen has not
          infringed any of the claims of the patent based on activities related
          to Enbrel(R) (etanercept) and Kineret(R) (anakinra).

          A copy of the press release is filed herewith as Exhibit 99.1 and the
          information contained therein is incorporated by reference into this
          Item 8.01 of this Current Report on Form 8-K.




ITEM 9.01 Financial Statements and Exhibits.

          (c)  The following exhibits are filed with this report

               Exhibit
               Number             Description
               ------             -----------
               99.1               Press release dated April 13, 2007




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                          ARIAD Pharmaceuticals, Inc.



                                          By:  /s/ Edward M. Fitzgerald
                                             -----------------------------------
                                               Edward M. Fitzgerald
                                               Senior Vice President,
                                               Finance and Corporate Operations,
                                               Chief Financial Officer


Date:    April 13, 2007




                                  EXHIBIT INDEX
                                  -------------

Exhibit
Number            Description
- ------            -----------
99.1              Press release dated April 13, 2007

EX-99.1

                                                                    Exhibit 99.1


   ARIAD Files Claim against Amgen and Wyeth Alleging Infringement
          of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)


    CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 13, 2007--ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has filed
a claim against Amgen Inc. and certain affiliated entities (Amgen) and
Wyeth alleging infringement of the pioneering U.S. patent covering
methods of treating human disease by regulating NF-(kappa)B
cell-signaling activity. The claim is in response to a lawsuit filed
by Amgen against ARIAD in the United States District Court for the
District of Delaware in April 2006 seeking declaratory judgment that
the claims of U.S. Patent No. 6,410,516 (the '516 Patent) are invalid
and that Amgen has not infringed any of the claims of the patent based
on activities related to Enbrel(R) (etanercept) and Kineret(R)
(anakinra).

    The '516 Patent is based on the pioneering discoveries made by
research groups led by Professors David Baltimore, Phillip Sharp and
Tom Maniatis at the Massachusetts Institute of Technology, The
Whitehead Institute for Biomedical Research, and Harvard University.
ARIAD is the exclusive licensee of the technology and patents. The
institutions have joined the lawsuit as co-plaintiffs. Wyeth, which
markets Enbrel with Amgen, was also named as a defendant in the
lawsuit.

    "Our assertion of an infringement claim against Amgen and Wyeth
highlights our strong belief in the validity and enforceability of our
NF-(kappa)B patent," said Harvey J. Berger, M.D., chairman and chief
executive officer of ARIAD.

    Enbrel is a tumor necrosis factor (TNF) blocker. Kineret is an
interleukin-1 (IL-1) receptor antagonist. TNF and IL-1 are cytokines
produced by the immune system.

    The '516 Patent was issued on June 25, 2002 and expires in 2019.
In May 2006, a jury in the United States District Court for the
District of Massachusetts found certain claims of the '516 Patent to
be valid and infringed by Eli Lilly and Company (Lilly) with respect
to Lilly's osteoporosis drug, Evista(R), and Lilly's septic shock
drug, Xigris(R). The claims at issue against Amgen and Wyeth are
different from those found valid and infringed by Lilly.

    About ARIAD

    ARIAD is engaged in the discovery and development of breakthrough
medicines to treat cancer by regulating cell signaling with small
molecules. The company is developing a comprehensive approach to
patients with cancer that addresses the greatest medical need -
aggressive and advanced-stage cancers for which current treatments are
inadequate. Medinol Ltd. also is developing stents and other medical
devices that deliver ARIAD's lead cancer product candidate to prevent
reblockage at sites of vascular injury following stent-assisted
angioplasty. ARIAD has an exclusive license to pioneering technology
and patents related to certain NF-(kappa)B treatment methods, and the
discovery and development of drugs to regulate NF-(kappa)B
cell-signaling activity, which may be useful in treating certain
diseases. Additional information about ARIAD can be found on the web
at http://www.ariad.com.

    Some of the matters discussed herein are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements are identified by the use of words
such as "may", "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe," and other words and terms of similar
meaning in connection with any discussion of future operating or
financial performance. Such statements are based on management's
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events, timing
and performance to differ materially from those expressed or implied
by such forward-looking statements. These risks include, but are not
limited to, risks and uncertainties regarding the design, endpoints
and timing of our Phase 3 clinical trial of AP23573, risks and
uncertainties regarding our ability to accurately estimate the timing
and actual R&D expenses and other costs associated with the
preclinical and clinical development and manufacture of our product
candidates, the adequacy of our capital resources and the availability
of additional funding, risks and uncertainties regarding our ability
to manufacture or have manufactured our product candidates on a
commercial scale, risks and uncertainties regarding our ability to
successfully recruit centers, enroll patients and conduct clinical
studies of product candidates, risks and uncertainties that clinical
trial results at any phase of development may be adverse or may not be
predictive of future results or lead to regulatory approval of any of
our or any partner's product candidates, risks and uncertainties of
third-party intellectual property claims relating to our and any
partner's product candidates, risks and uncertainties related to the
potential acquisition of or other strategic transaction regarding the
minority stockholders' interests in our 80%-owned subsidiary, ARIAD
Gene Therapeutics, Inc., and risks and uncertainties relating to
regulatory oversight, the timing, scope, cost and outcome of legal and
patent office proceedings concerning our NF-(kappa)B patent portfolio
including the matters discussed in this release, future capital needs,
key employees, dependence on collaborators and manufacturers, markets,
economic conditions, products, services, prices, reimbursement rates,
competition and other factors detailed in the Company's public filings
with the Securities and Exchange Commission. The information contained
in this document is believed to be current as of the date of original
issue. The Company does not intend to update any of the
forward-looking statements after the date of this document to conform
these statements to actual results or to changes in the Company's
expectations, except as required by law.


    CONTACT: ARIAD Pharmaceuticals, Inc.
             Investors
             Ed Fitzgerald, 617-621-2345
             or
             Pure Communications
             Media
             Andrea Johnston, 910-681-1088